243 related articles for article (PubMed ID: 35007812)
1. Benefits of immunonutrition in patients with head and neck cancer receiving chemoradiation: A phase II randomized, double-blind study.
Dechaphunkul T; Arundon T; Raungkhajon P; Jiratrachu R; Geater SL; Dechaphunkul A
Clin Nutr; 2022 Feb; 41(2):433-440. PubMed ID: 35007812
[TBL] [Abstract][Full Text] [Related]
2. A double-blind phase III trial of immunomodulating nutritional formula during adjuvant chemoradiotherapy in head and neck cancer patients: IMPATOX.
Boisselier P; Kaminsky MC; Thézenas S; Gallocher O; Lavau-Denes S; Garcia-Ramirez M; Alfonsi M; Cupissol D; de Forges H; Janiszewski C; Geoffrois L; Sire C; Senesse P;
Am J Clin Nutr; 2020 Dec; 112(6):1523-1531. PubMed ID: 32936874
[TBL] [Abstract][Full Text] [Related]
3. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study.
Hong RL; Hsiao CF; Ting LL; Ko JY; Wang CW; Chang JTC; Lou PJ; Wang HM; Tsai MH; Lai SC; Liu TW
Ann Oncol; 2018 Sep; 29(9):1972-1979. PubMed ID: 30016391
[TBL] [Abstract][Full Text] [Related]
4. A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (Endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: Long-term outcomes update.
Li Y; Tian Y; Jin F; Wu W; Long J; Ouyang J; Zhou Y
Curr Probl Cancer; 2020 Feb; 44(1):100492. PubMed ID: 32035692
[TBL] [Abstract][Full Text] [Related]
5. Raltitrexed versus 5-fluorouracil with cisplatin and concurrent radiotherapy for locally advanced nasopharyngeal carcinoma: An open labeled, randomized, controlled, and multicenter clinical trial.
Yan P; Yin H; Guo W; Sun X; Li F; Huang S; Bian X; Wang F; Zhang F; Wang B; Zhou H; Zhou C; Yin L; Jiang X; Jiang N; Wu J; Liu J; Song D; He X
Cancer Med; 2020 Sep; 9(17):6166-6172. PubMed ID: 32657029
[TBL] [Abstract][Full Text] [Related]
6. Randomized, Double-Blind, Placebo-Controlled Trial of Shuanghua Baihe Tablets to Prevent Oral Mucositis in Patients With Nasopharyngeal Cancer Undergoing Chemoradiation Therapy.
Zheng B; Zhu X; Liu M; Yang Z; Yang L; Lang J; Shi M; Wu G; He X; Chen X; Xi X; Zhao D; Zhu G
Int J Radiat Oncol Biol Phys; 2018 Feb; 100(2):418-426. PubMed ID: 29353657
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of thalidomide in preventing oral mucositis in patients with nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: A multicenter, open-label, randomized controlled trial.
Liang L; Liu Z; Zhu H; Wang H; Wei Y; Ning X; Shi Z; Jiang L; Lin Z; Yan H; Wang R; Hu K
Cancer; 2022 Apr; 128(7):1467-1474. PubMed ID: 34910297
[TBL] [Abstract][Full Text] [Related]
8. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study.
Yokota T; Ogawa T; Takahashi S; Okami K; Fujii T; Tanaka K; Iwae S; Ota I; Ueda T; Monden N; Matsuura K; Kojima H; Ueda S; Sasaki K; Fujimoto Y; Hasegawa Y; Beppu T; Nishimori H; Hirano S; Naka Y; Matsushima Y; Fujii M; Tahara M
BMC Cancer; 2017 May; 17(1):314. PubMed ID: 28476132
[TBL] [Abstract][Full Text] [Related]
10. Oral mucositis prevention by low-level laser therapy in head-and-neck cancer patients undergoing concurrent chemoradiotherapy: a phase III randomized study.
Gouvêa de Lima A; Villar RC; de Castro G; Antequera R; Gil E; Rosalmeida MC; Federico MH; Snitcovsky IM
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):270-5. PubMed ID: 21163585
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled trial of probiotics to reduce the severity of oral mucositis induced by chemoradiotherapy for patients with nasopharyngeal carcinoma.
Jiang C; Wang H; Xia C; Dong Q; Chen E; Qiu Y; Su Y; Xie H; Zeng L; Kuang J; Ao F; Gong X; Li J; Chen T
Cancer; 2019 Apr; 125(7):1081-1090. PubMed ID: 30521105
[TBL] [Abstract][Full Text] [Related]
12. Prophylaxis of Oral Mucositis with Iodine Solution during Concurrent Chemoradiation of Head and Neck Cancer: Preliminary Results of a Double-Blind, Randomized Controlled Trial.
Namuangchan Y; Chailertwanich O; Susinsamphan S; Supakalin N; Supaadirek C; Krusun S; Pesee M; Thamronganantasakul K
Asian Pac J Cancer Prev; 2023 Jul; 24(7):2445-2454. PubMed ID: 37505779
[TBL] [Abstract][Full Text] [Related]
13. Randomized placebo-controlled phase II trial of high-dose melatonin mucoadhesive oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing radiation therapy concurrent with systemic treatment.
Lozano A; Marruecos J; Rubió J; Farré N; Gómez-Millán J; Morera R; Planas I; Lanzuela M; Vázquez-Masedo MG; Cascallar L; Giralt J; Escames G; Valentí V; Grima P; Bosser R; Tarragó C; Mesía R
Clin Transl Oncol; 2021 Sep; 23(9):1801-1810. PubMed ID: 33738704
[TBL] [Abstract][Full Text] [Related]
14. Effect of Concurrent Chemoradiotherapy With Nedaplatin vs Cisplatin on the Long-term Outcomes of Survival and Toxic Effects Among Patients With Stage II to IVB Nasopharyngeal Carcinoma: A 5-Year Follow-up Secondary Analysis of a Randomized Clinical Trial.
Tang QN; Liu LT; Qi B; Guo SS; Luo DH; Sun R; Sun XS; Chen DP; Guo L; Mo HY; Wang P; Liu SL; Liang YJ; Li XY; Yang ZC; Chen QY; Mai HQ; Tang LQ
JAMA Netw Open; 2021 Dec; 4(12):e2138470. PubMed ID: 34928359
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
[TBL] [Abstract][Full Text] [Related]
16. A phase III randomized study comparing neoadjuvant chemotherapy with concurrent chemotherapy combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma: updated long-term survival outcomes.
Xu T; Zhu G; He X; Ying H; Hu C
Oral Oncol; 2014 Feb; 50(2):71-6. PubMed ID: 24315404
[TBL] [Abstract][Full Text] [Related]
17. Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy.
Bossi P; Bergamini C; Miceli R; Cova A; Orlandi E; Resteghini C; Locati L; Alfieri S; Imbimbo M; Granata R; Mariani L; Iacovelli NA; Huber V; Cavallo A; Licitra L; Rivoltini L
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):959-966. PubMed ID: 27745982
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus neoadjuvant chemotherapy plus concurrent chemoradiotherapy for ascending or descending types of nasopharyngeal carcinoma: A retrospective study.
Lin Q; Lu L; Wang X; Lin Y; Chen Y; Chen H; Chen S; Lin S; Zhang Y; Zheng P; Chen X
Am J Otolaryngol; 2022; 43(1):103193. PubMed ID: 34509080
[TBL] [Abstract][Full Text] [Related]
19. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.
Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Castro A; Licitra L; Adelstein D; Vermorken JB
Oncologist; 2017 Sep; 22(9):1056-1066. PubMed ID: 28533474
[TBL] [Abstract][Full Text] [Related]
20. Ten-year outcomes of survival and toxicity for a phase III randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma.
Li XY; Chen QY; Sun XS; Liu SL; Yan JJ; Guo SS; Liu LT; Xie HJ; Tang QN; Liang YJ; Wen YF; Guo L; Mo HY; Chen MY; Sun Y; Ma J; Tang LQ; Mai HQ
Eur J Cancer; 2019 Mar; 110():24-31. PubMed ID: 30739837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
